zbMATH — the first resource for mathematics

Revisit Kaplan-Meier estimator in estimating QAL survival distributions. (English) Zbl 1423.62126
Summary: Quality-adjusted lifetime (QAL) is an important component in evaluation of clinical trials. In a seminal paper, R. D. Gelber et al. [Biometrics 45, No. 3, 781–795 (1989; Zbl 0715.62262)] claimed that the Kaplan-Meier estimator is inconsistent in estimating the distribution of QAL under the presence of censoring. However, in this article, we show that, with appropriate censoring indexing, the Kaplan-Meier estimator actually is consistent in some practically important QAL data settings.
62N02 Estimation in survival analysis and censored data
62G05 Nonparametric estimation
Full Text: DOI
[1] Bracewell, R., The impulse symbol. Ch. 5, 74-104, (2000), New York
[2] Cole, B. F.; Gelber, R. D.; Gelber, S.; Mukhopadhyay, P., A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer, J. Biopharm. Stat., 14, 111-124, (2004)
[3] Gao, F.; Wee, J.; Wong, H. B.; Machin, D., Quality-of-life-adjusted survival analysis of concurrent chemo radiotherapy for locally advanced (nonmetastatic) nasopharyngeal cancer, Int. J. Radiat. Oncol. Biol. Phys., 78, 454-460, (2010)
[4] Gelber, R. D.; Goldhirsch, A., A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer, J. Clin. Oncol., 4, 1772-1779, (1986)
[5] Gelber, R. D.; Goldhirsch, A.; Castiglione, M.; Price, K.; Isley, M.; Coates, A.; Salmon, S. E (ed.), For the Ludwig breast cancer study group. Time without symptoms and toxicity (TWiST): A quality-of-life-oriented endpoint to evaluate adjuvant therapy, 379-391, (1987), Orlando, FL
[6] Gelber, R. D.; Gelman, R. S.; Goldhirsch, A., A quality-of-life oriented endpoint for comparing therapies, Biometrics, 45, 781-795, (1989) · Zbl 0715.62262
[7] Glasziou, P. P.; Simes, R. J.; Gelber, R. D., Quality adjusted survival analysis, Stat. Med., 9, 1259-1276, (1990)
[8] Goldhirsch, A.; Gelber, R. D.; Simes, R. J.; Glasziou, P.; Coates, A., For the Ludwig breast cancer study group. Costs and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis, J. Clin. Oncol., 7, 36-44, (1989)
[9] Huang, Y.; Louis, T. A., Nonparametric estimation of the joint distribution of survival time and mark variables, Biometrika, 85, 785-798, (1998) · Zbl 0921.62035
[10] Kaplan, E. L.; Meier, P., Nonparametric estimation from incomplete observations, J. Am. Stat. Assoc., 53, 457-481, (1958) · Zbl 0089.14801
[11] Korn, E. L., On estimating the distribution function for quality of life in cancer clinical trials, Biometrika, 80, 535-540, (1993) · Zbl 0800.62704
[12] Pradhan, B.; Dewanji, A.; Sengupta, D., Parametric estimation of quality adjusted life-time (QAL) distribution in simple illness-death model, Commun. Stat. Theory Methods, 39, 77-93, (2010) · Zbl 1182.62190
[13] Wellner, J. A., Asymptotic optimality of the product limit estimator, Ann. Stat., 10, 595-602, (1982) · Zbl 0489.62036
[14] Zhao, H.; Tsiatis, A. A., A consistent estimator for the distribution of quality adjusted survival time, Biometrika, 84, 339-348, (1997) · Zbl 0882.62110
[15] Zhao, H.; Tsiatis, A. A., Efficient estimator for the distribution of quality-adjusted survival time, Biometrics, 55, 1101-1107, (1999) · Zbl 1059.62742
[16] Zhao, H.; Tsiatis, A. A., Estimating mean quality adjusted lifetime with censored data, Sankhya Ser. B Special Issue Biostat., 62, 175-188, (2000) · Zbl 0973.62105
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. It attempts to reflect the references listed in the original paper as accurately as possible without claiming the completeness or perfect precision of the matching.